披衣菌感染感染诊断市场 - 全球产业规模、份额、趋势、机会及预测（按检测类型、感染类型、最终用户、地区和竞争格局划分，2021-2031年）

全球沙眼衣原体感染诊断市场预计将从 2025 年的 7.7112 亿美元成长到 2031 年的 11.3599 亿美元，复合年增长率为 6.67%。

这些诊断方法主要透过检查室分析和快速检测套组进行，利用核酸增幅检查(NAT) 技术检测患者检体中的披衣菌感染衣原体。市场成长的驱动因素包括全球性行为感染传染病的持续流行以及各国政府为确保早期发现而大力推行的筛检。例如，美国疾病管制与预防中心 (CDC) 发布的初步数据显示，2024 年美国约有 150 万例披衣菌感染病例，这凸显了儘管年度感染率有所波动，但有效检测的必要性依然存在。

然而，沙眼衣原体感染面临一个重大障碍，因为其通常无症状，这降低了患者就医的紧迫性。由于许多感染者没有临床症状，他们往往得不到诊断和治疗，这限制了每年进行的诊断检测总数。这种情况导致人们更加依赖主动的公共卫生项目，而不是有症状的患者就诊，这限制了在常规筛检尚未严格实施的地区市场成长。

市场驱动因素

全球披衣菌感染衣原体感染疾病的不断增加是推动市场成长的主要因素，因此需要强有力的监测来遏制这种广泛传播的细菌。随着感染病例的持续增加，医疗系统正着力进行广泛的筛检，以发现未接受治疗的感染者并预防不孕症等併发症，从而对频繁的检查室检测产生了持续的需求。根据 MedTech Dive 2025 年 3 月发表的一篇报导《FDA核准首批三种性行为感染(STI) 家用检测套组》，美国疾病管制与预防中心 (CDC) 的数据显示，2023 年美国报告的梅毒、淋病和披衣菌感染病例超过 240 万例，凸显了持续监测的必要性。同样，英国卫生安全局 (UKHSA) 2025 年 12 月的一份报告指出，2024 年英格兰对 15 至 24 岁的年轻女性进行了 601,295 次披衣菌感染检测，这表明英国开展了大规模的国家筛检工作。

此外，快速照护现场(POC) 技术的进步和家用检测套组需求的不断增长，正透过分散式医疗服务管道改变市场格局。这些创新克服了隐私和便利性方面的障碍，鼓励那些原本可能避免去诊所就诊的人寻求诊断，同时监管机构也日益认可这些解决方案的有效性，并推动其更广泛应用。根据 CIDRAP 于 2025 年 3 月报道，美国食品药物管理局(FDA)核准了首批由 Visby Medical 开发的商用家用检测套组，用于检测披衣菌感染、淋病和滴虫病。这种以使用者为主导的检测方式，透过识别传统临床方法难以发现的无症状感染者，提高了检测率。

市场挑战

全球沙眼衣原体感染诊断市场面临的主要障碍之一是该感染通常无症状，这抑制了人们自愿检测的动机。大多数感染者不会出现明显症状，因此缺乏立即就医或接受筛检的动机。这种缺乏紧迫感的情况显着降低了患者主导就诊的次数，迫使市场更依赖政府资助的筛检项目，而非消费者的自发性需求。因此，在公共卫生资源有限或筛检强制措施执行不力的地区，检测量会急剧下降，直接限制诊断试剂生产商的收入潜力。

近期监测数据印证了这一趋势，显示检测活动的减少导致检出率下降。例如，英国卫生安全局报告称，2025年披衣菌感染的诊断数量比2024年下降了13%。这一下降主要是由于年轻人检测量的减少所致。这种下降趋势凸显了缺乏临床症状如何导致感染未被发现，从而有效地缩小了诊断检测解决方案的潜在市场。

市场趋势

多重核酸增幅检查扩增检测 (MNA) 的广泛应用正在重塑诊断流程，它能够同时检测披衣菌感染披衣菌和伴随感染疾病，例如淋病奈瑟菌和阴道毛滴虫。这一趋势满足了临床对全面性健康评估的需求，与单标靶检测相比，单次检测即可识别多种病原体，从而改善患者管理和检查室效率。 Hologic 公司在 2025 年 11 月发布的 2025 财年第四季财报中报告称，其分子诊断业务收入成长了 1.2%。这一增长主要得益于先进多重检测板（例如 BV CV/TV 检测）的广泛应用，该检测板在一个自动化平台上整合了阴道炎和性行为感染病原体的检测。

同时，以药局为基础的去中心化筛检模式的兴起，正在透过将诊断服务引入本地零售环境，重新定义病患的就医途径，消除了以往就医的障碍。公共卫生计画正利用社区药局分发自取样试剂盒，并推广即时干预，从而有效地涵盖那些可能不会定期就医的无症状人群。例如，2025年2月，萨里郡议会在其「2025-2028年披衣菌感染治疗和筛检」协议中正式规定了服务规范，要求社区药房主动向25岁以下性活跃人群提供披衣菌感染检测套组。这凸显了感染率管理方面向以药房为主导的基础设施的策略转变。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球披衣菌感染感染诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依检测方法（培养试验、核酸增幅检查（NAAT）、直接萤光抗体试验、血清学试验、其他）
  • 依感染部位分类（生殖器沙眼衣原体感染、直肠沙眼衣原体感染、眼部沙眼衣原体感染）
  • 依最终使用者（医院、专科诊所、诊断中心）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美披衣菌感染感染诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲披衣菌感染感染诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区披衣菌感染感染诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲披衣菌感染感染诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美披衣菌感染感染诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球披衣菌感染感染诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca Plc
• Teva Pharmaceutical Industries Limited
• bioMerieux SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Chlamydia Infection Diagnostics Market is projected to expand from USD 771.12 Million in 2025 to USD 1135.99 Million by 2031, reflecting a CAGR of 6.67%. These diagnostics primarily involve laboratory assays and rapid testing kits that use Nucleic Acid Amplification Tests to detect Chlamydia trachomatis in patient samples. Market growth is underpinned by the continuing global prevalence of sexually transmitted infections and strong government mandates for screening to ensure early detection. For instance, the Centers for Disease Control and Prevention reported provisional data showing approximately 1.5 million chlamydia cases in the U.S. in 2024, highlighting the persistent need for effective testing despite variations in annual infection rates.

However, the market faces a significant hurdle due to the frequently asymptomatic nature of chlamydia, which reduces the urgency for patients to seek medical advice. Since many infected individuals show no clinical symptoms, they often go undiagnosed and untreated, which limits the total number of diagnostic tests conducted each year. This situation creates a reliance on proactive public health programs rather than symptomatic patient visits, thereby restricting market growth in areas where routine screening is not rigorously enforced.

Market Driver

The rising global incidence of Chlamydia trachomatis infections serves as a major market driver, requiring strong surveillance to control the spread of this widespread bacterium. As transmission continues, healthcare systems are emphasizing broad screening to detect untreated individuals and prevent complications like infertility, fueling a steady demand for high-volume laboratory testing. According to a March 2025 MedTech Dive article titled "FDA OKs first at-home test for 3 STIs," CDC data revealed that over 2.4 million cases of syphilis, gonorrhea, and chlamydia were reported in the U.S. in 2023, reinforcing the necessity for ongoing monitoring. Similarly, the UK Health Security Agency's December 2025 report noted that 601,295 chlamydia tests were conducted on young women aged 15 to 24 in England during 2024, demonstrating the vast scale of national screening efforts.

Additionally, the growth of rapid Point-of-Care (POC) technologies and the increasing demand for at-home testing kits are transforming the market by decentralizing care access. These innovations overcome barriers regarding privacy and convenience, prompting individuals who might avoid clinics to seek diagnosis, while regulatory agencies are increasingly validating these solutions for wider use. As reported by CIDRAP in March 2025, the U.S. FDA authorized the first over-the-counter, at-home test from Visby Medical that detects chlamydia, gonorrhea, and trichomoniasis. This move toward user-initiated testing improves detection rates by identifying asymptomatic cases often missed by traditional clinical methods.

Market Challenge

A major obstacle hindering the Global Chlamydia Infection Diagnostics Market is the often asymptomatic nature of the infection, which discourages voluntary testing. Since most infected individuals lack noticeable symptoms, they feel little immediate motivation to seek medical care or undergo screening. This lack of urgency significantly lowers the volume of patient-initiated visits, making the market heavily reliant on government-funded screening programs rather than organic consumer demand. Consequently, when public health resources are limited or screening mandates are not strictly enforced, testing numbers fall sharply, directly restricting the revenue potential for diagnostic manufacturers.

Recent surveillance data confirms this trend, showing that decreased testing activity leads to lower detection rates. For example, the UK Health Security Agency reported in 2025 that chlamydia diagnoses dropped by 13 percent in 2024 compared to the prior year, a decline largely driven by reduced testing volumes among young adults. This contraction illustrates how the lack of clinical symptoms allows infections to remain undetected, effectively reducing the addressable market for diagnostic testing solutions.

Market Trends

The widespread adoption of Multiplex Nucleic Acid Amplification Assays is reshaping diagnostic workflows by allowing the simultaneous detection of Chlamydia trachomatis and co-infections like Neisseria gonorrhoeae and Trichomonas vaginalis. This trend meets the clinical need for comprehensive sexual health profiling, as identifying multiple pathogens in a single test enhances patient management and laboratory efficiency compared to single-target tests. In its "Financial Results for Fourth Quarter of Fiscal 2025" released in November 2025, Hologic, Inc. reported a 1.2 percent increase in molecular diagnostics revenue, a growth attributed to the rising use of their advanced multiplex panels, such as the BV CV/TV assays, which consolidate testing for vaginitis and sexually transmitted pathogens on automated platforms.

Concurrently, the rise of decentralized pharmacy-based screening models is redefining patient access by bringing diagnostic services into community retail environments, thereby eliminating obstacles associated with traditional clinical visits. Public health programs are increasingly leveraging local pharmacies to distribute self-collection kits and facilitate immediate intervention, effectively reaching asymptomatic populations who might otherwise skip routine medical appointments. For instance, in February 2025, Surrey County Council formalized a service specification in its "Chlamydia Treatment and Screening 2025-28" agreement, requiring community pharmacies to actively provide chlamydia screening kits to sexually active individuals under 25, highlighting the strategic pivot toward pharmacy-led infrastructure in managing infection rates.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca Plc
• Teva Pharmaceutical Industries Limited
• bioMerieux SA

Report Scope

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chlamydia Infection Diagnostics Market, By Test Type

• Culture Test
• Nucleic Acid Amplification Test (NAAT)
• Direct Fluorescent Antibody Test
• Serology Test and Other

Chlamydia Infection Diagnostics Market, By Type of Infections

• Genital Chlamydia Infection
• Rectal Chlamydia Infection
• Ocular Chlamydia Infection

Chlamydia Infection Diagnostics Market, By End User

• Hospitals
• Specialty Clinics
• Diagnostics Centre

Chlamydia Infection Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chlamydia Infection Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)
  • 5.2.2. By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
  • 5.2.3. By End User (Hospitals, Specialty Clinics, Diagnostics Centre)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Chlamydia Infection Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Type of Infections
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chlamydia Infection Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Type of Infections
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Chlamydia Infection Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Type of Infections
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Chlamydia Infection Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Type of Infections
      • 6.3.3.2.3. By End User

7. Europe Chlamydia Infection Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Type of Infections
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chlamydia Infection Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Type of Infections
      • 7.3.1.2.3. By End User
  • 7.3.2. France Chlamydia Infection Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Type of Infections
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Chlamydia Infection Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Type of Infections
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Chlamydia Infection Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Type of Infections
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Chlamydia Infection Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Type of Infections
      • 7.3.5.2.3. By End User

8. Asia Pacific Chlamydia Infection Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Type of Infections
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Chlamydia Infection Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Type of Infections
      • 8.3.1.2.3. By End User
  • 8.3.2. India Chlamydia Infection Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Type of Infections
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Chlamydia Infection Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Type of Infections
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Chlamydia Infection Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Type of Infections
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Chlamydia Infection Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Type of Infections
      • 8.3.5.2.3. By End User

9. Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Type of Infections
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Chlamydia Infection Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Type of Infections
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Chlamydia Infection Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Type of Infections
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Chlamydia Infection Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Type of Infections
      • 9.3.3.2.3. By End User

10. South America Chlamydia Infection Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Type of Infections
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Chlamydia Infection Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Type of Infections
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Chlamydia Infection Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Type of Infections
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Chlamydia Infection Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Type of Infections
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Chlamydia Infection Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories
• 15.3. Hologic, Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. Bio-Rad Laboratories, Inc
• 15.6. Quidel Corporation
• 15.7. DiaSorin SpA
• 15.8. AstraZeneca Plc
• 15.9. Teva Pharmaceutical Industries Limited
• 15.10. bioMerieux SA

16. Strategic Recommendations

17. About Us & Disclaimer